Patents by Inventor David S. Baker

David S. Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12231414
    Abstract: Techniques are disclosed relating to multiway communications. In some embodiments, a first electronic device initiates a multiway call between a plurality of electronic devices and exchanges a first secret with a first set of electronic devices participating during a first portion of the multiway call, the first secret being used to encrypt traffic between the first set of electronic devices. The first electronic device receives an indication that first set of participating electronic devices has changed and, in response to the indication, exchanges a second secret with a second set of electronic devices participating during a second portion of the multiway call, the second secret being used to encrypt traffic between the second set of participating electronic devices. In some embodiments, the indication identifies a second electronic device as leaving the multiway call, and the second secret is not exchanged with the second electronic device.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: February 18, 2025
    Assignee: Apple Inc.
    Inventors: Yan Yang, Jin Hyung Park, Joe S. Abuan, Berkat S. Tung, Sean P. Devlin, Vu H. Chiem, Jose A. Lozano Hinojosa, Thomas P. Devanneaux, Vladimir Goupenko, Hsien-Po Shiang, Daniel B. Pollack, Mark M. Xue, David J. Steele, Yu Xing, Ryan W. Baker, Christopher M. Garrido, Ming Jin
  • Patent number: 12220229
    Abstract: One or more radar sensors can be used to monitor patients in a variety of different environments and embodiments. In one embodiment, radar sensors can be used to monitor a patient's breathing, including monitoring of tidal volume, chest expansion distance, breathing rate, etc. In another embodiment, a patient position can be monitored in a patient bed, which can be used as feedback for control of bladders of a patient bed. Additional embodiments are described herein.
    Type: Grant
    Filed: December 14, 2023
    Date of Patent: February 11, 2025
    Assignee: Hill-Rom Services, Inc.
    Inventors: Stacey A. Fitzgibbons, David L. Ribble, Eric R. Meyer, Michael S. Hood, Gregory J. Shannon, Yue Wang, Charles A. Lachenbruch, Steven D. Baker
  • Patent number: 12168017
    Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: December 17, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Publication number: 20240398705
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: July 25, 2024
    Publication date: December 5, 2024
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Patent number: 12070466
    Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: August 27, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Publication number: 20240165098
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: December 14, 2023
    Publication date: May 23, 2024
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20240139166
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition comprises a low concentration of an ophthalmic agent for treatment of presbyopia. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 2, 2024
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Patent number: 11896588
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: February 13, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 11890277
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: February 6, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 11883390
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: January 30, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Publication number: 20230381016
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of a muscarinic antagonist or an ophthalmic agent for treatment of an ophthalmic disorder or condition in a preservative-free ophthalmic formulation. Further disclosed herein include an ophthalmic composition including a low concentration of a muscarinic antagonist or an ophthalmic agent and deuterated water. Also disclosed herein are methods of treating an ophthalmic condition or disease by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: August 1, 2023
    Publication date: November 30, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20230092957
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 23, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20230091109
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 23, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20230093205
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 23, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Patent number: 11596625
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 7, 2023
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Publication number: 20230041788
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Further disclosed herein is an ophthalmic including a low concentration of an ophthalmic agent and various ratios of water to deuterated water.
    Type: Application
    Filed: December 15, 2020
    Publication date: February 9, 2023
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
  • Publication number: 20220409605
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: December 29, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20220409604
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: December 29, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20220409603
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: December 29, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • Publication number: 20220378775
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: February 25, 2022
    Publication date: December 1, 2022
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI